Autosomal recessive cerebellar ataxia

Autosomal recessive cerebellar ataxia (ARCA) refers to a large and heterogeneous group of inherited neurological disorders characterized by progressive cerebellar dysfunction due to degeneration or abnormal development of the cerebellum and its connections. These conditions are inherited in an autosomal recessive manner, meaning an affected individual must carry two pathogenic variants (one from each parent) in the causative gene. The group encompasses numerous distinct subtypes, including Friedreich ataxia (the most common form), ataxia-telangiectasia, ataxia with oculomotor apraxia types 1 and 2, autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), and many others. The hallmark clinical feature shared across these conditions is progressive cerebellar ataxia, which manifests as impaired coordination and balance, unsteady gait, difficulty with fine motor tasks, and dysarthria (slurred speech). Depending on the specific subtype, additional body systems may be affected, including the peripheral nervous system (sensory or motor neuropathy), the spinal cord (spasticity), the eyes (oculomotor abnormalities, retinal degeneration), the heart (cardiomyopathy, particularly in Friedreich ataxia), and metabolic systems (diabetes, vitamin E deficiency). Some forms are associated with cognitive impairment, immune deficiency, or elevated cancer risk (as in ataxia-telangiectasia). Age of onset is variable across the group but most commonly presents in childhood or adolescence. Diagnosis typically involves clinical evaluation, neuroimaging (often showing cerebellar atrophy), electrophysiological studies, biochemical testing, and increasingly, genetic testing through targeted panels or whole-exome sequencing. Treatment remains largely supportive and symptomatic, including physical therapy, occupational therapy, speech therapy, and management of associated complications such as cardiomyopathy or diabetes. For some specific subtypes, targeted interventions exist, such as vitamin E supplementation in ataxia with vitamin E deficiency (AVED). Several clinical trials are ongoing for disease-modifying therapies, particularly for Friedreich ataxia, where omaveloxolone (Skyclarys) has received regulatory approval in some jurisdictions.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Autosomal recessive cerebellar ataxia